AngioGenex files patent for small molecule id inhibitors for cancer

Both the in vitro and in vivo studies indicate that small molecule inhibitors of the Id proteins will block angiogenesis and malignant transformation of cells responsible for tumor growth in man, and are likely to be orally active.

Richard Salvador, president and CEO, said: “The identification of these lead molecules and the filing of this patent constitute major milestones in the company’s goal to develop orally active anticancer drugs. The work embodied in this patent establishes the drugability of the Id proteins as targets allowing the Company to move forward with the preclinical work required to bring these molecules into the clinic.”

Dr William Garland, vice president and head of R&D, said: “Inhibition of the Id proteins by these small molecules is unlikely to cause serious adverse effects in patients since they are not known to be required for the normal function of cells of the body. Their only function, with minor exceptions, is to promote blood vessel formation into tumors.”